DUBLIN--(BUSINESS WIRE)--The "Premature Labor (Tocolysis) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report provides an overview of the Premature Labor (Women's Health) pipeline landscape.
Preterm labor or premature labor is defined as labor that begins before completion of 36 weeks of pregnancy. Symptoms include sensation of pelvic or lower abdominal pressure, mild abdominal cramps, diarrhea, vaginal spotting or bleeding and constant low, dull backache. Treatment includes corticosteroids and tocolytics.
The report provides comprehensive information on the therapeutics under development for Premature Labor (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Premature Labor (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Premature Labor (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Labor (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Premature Labor (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Premature Labor (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Premature Labor (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Premature Labor (Women's Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Premature Labor (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Premature Labor (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Therapeutics Development
- Therapeutics Assessment
- Companies Involved in Therapeutics Development
- Drug Profiles
- Dormant Projects
- Discontinued Products
- Product Development Milestones
- Dare Bioscience Inc
- GlaxoSmithKline Plc
- ILIAS Biologics Inc
- Lipocine Inc
- ObsEva SA
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/7dqzwx